Friday, July 20, 2007

High Dose Combination Therapy Better Than Monotherapy For Lowering Hypertension

Patients with hypertension who receive aliskiren in combination with valsartan at the highest recommended doses experience much greater reductions in blood pressure, compared to monotherapy with either drug. The combined therapy's tolerability profile is similar to the monotherapy's with either drug.

You can read about this in The Lancet, this week's issue. A comment which accompanies the article says that it is doubtful this will ever make it into general practice or primary prevention in specialist care because of the potentially fatal side-effects of high blood potassium.

No comments: